Status:
COMPLETED
Effects of Caffeine on Anxiety, Emotional Processing, Approach-avoidance Behavior, and Interoception in Panic Disorder
Lead Sponsor:
Uppsala University
Conditions:
Panic Disorder
Healthy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The current study is a placebo-controlled, double-blind, randomized controlled study using a cross-over design, including participants with Panic disorder and healthy controls. The study's primary ai...
Detailed Description
Hypotheses Self-reported anxiety during resting state * Participants with Panic disorder will report higher resting-state levels of anxiety and negative emotions during the caffeine condition vs the...
Eligibility Criteria
Inclusion
- Panic disorder group: Primary diagnosis of panic disorder.
- Healthy control group: No current or history of psychiatric disorders.
- All participants (Panic disorder and healthy): Weekly caffeine consumption ≤ 300 mg.
Exclusion
- History of severe psychiatric disorder (e.g. schizophrenia). Somatic or neurological conditions (e.g. hypertension and heart condition). Ongoing treatment with psychotropic medication or treatment with psychotropic medication which has been discontinued within 2 months. Other ongoing treatments that may confound the results. Current drug or alcohol abuse/dependency. Habitual nicotine use. Uncorrected visual or hearing impairment. Pregnancy.
Key Trial Info
Start Date :
March 16 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 19 2023
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT05261594
Start Date
March 16 2022
End Date
March 19 2023
Last Update
April 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uppsala university, Department of Medical Sciences, Psychiatry
Uppsala, Sweden, 75185